| 1) Gazit et al | ya nuna cewa "alurar rigakafi na SARS-CoV-2-naïve suna da ninki 13 (95% CI, 8-21) ya karu don kamuwa da cuta tare da bambance-bambancen Delta idan aka kwatanta da waɗanda suka kamu da cutar a baya." Lokacin daidaitawa don lokacin cutar / alurar riga kafi, akwai haɗarin haɓakar sau 27 (95% CI, 13-57). |
| 2) Acharya et al. | Yin watsi da haɗarin kamuwa da cuta, an ba da cewa wani ya kamu da cutar, Acharya et al. An gano "babu wani babban bambanci a cikin ƙimar ƙimar zagayowar tsakanin allurar rigakafi da marasa alurar riga kafi, asymptomatic da ƙungiyoyi masu alamun kamuwa da SARS-CoV-2 Delta." |
| 3) Riemersma et al. | An gano "babu wani bambanci a cikin nau'in kwayar cutar yayin kwatanta wadanda ba a yi wa allurar rigakafi da wadanda ke da allurar rigakafin cutar ba." Bugu da ƙari kuma, mutanen da ke fama da ciwon maganin rigakafi akai-akai suna gwada inganci tare da nauyin hoto mai kama da ikon zubar da ƙwayoyin cuta." Sakamako sun nuna cewa "idan mutanen da aka yi musu allurar sun kamu da bambance-bambancen delta, suna iya zama tushen watsa SARS-CoV-2 ga wasu." Sun ba da rahoton "ƙananan ƙimar Ct (<25) a cikin 212 na 310 da aka yi cikakken alurar riga kafi (68%) da 246 na 389 (63%) marasa alurar riga kafi. Gwajin wani yanki na waɗannan ƙananan samfuran Ct ya nuna kamuwa da cutar SARS-CoV-2 a cikin 15 na 17 samfurori (88%) na mutane 37 da ba a yi musu allurar rigakafi mutane." |
| 4) Chemaili et al. | A wani bincike daga Qatar. Chemaili et al. an ba da rahoton ingancin maganin alurar riga kafi (Pfizer) akan cuta mai tsanani da mutuwa, tare da inganci a cikin kewayon 85-95% aƙalla har zuwa makonni 24 bayan kashi na biyu. Sabanin haka, tasirin kamuwa da cuta ya ragu zuwa kusan 30% a makonni 15-19 bayan kashi na biyu. |
| 5) Riemersma et al. | Daga Wisconsin, Riemersma et al. An ba da rahoton cewa mutanen da aka yi wa allurar rigakafin da suka kamu da bambance-bambancen Delta na iya yada SARS-CoV-2 ga wasu. Sun sami babban nauyin kwayar cutar hoto a cikin mutanen da ba a yi musu allurar rigakafi ba da kuma wadanda aka yi musu alurar riga kafi (68% da 69% bi da bi, 158/232 da 156/225). Haka kuma, a cikin mutanen asymptomatic, sun gano manyan lodin hoto (29% da 82% bi da bi) a cikin waɗanda ba a yi musu allurar ba da kuma waɗanda aka yi musu bi da bi. Wannan yana nuna cewa waɗanda aka yi wa alurar riga kafi za su iya kamuwa da su, suna tashar jiragen ruwa, su yi noma, da kuma watsa kwayar cutar cikin sauri da rashin sani. |
| 6) Subramanian | Subramanian ya ba da rahoton cewa "a matakin ƙasa, da alama babu wata alaƙa da za a iya ganewa tsakanin adadin yawan mutanen da aka yi wa cikakken rigakafin cutar da sabbin shari'o'in COVID-19." Idan aka kwatanta kananan hukumomi 2947 a Amurka, an sami raguwar kararraki a wuraren da aka yi wa rigakafin. A takaice dai, babu wata ma'ana da za a iya ganewa. |
| 7) Chau et al. | ya kalli watsa bambance-bambancen SARS-CoV-2 Delta tsakanin ma'aikatan kiwon lafiya da aka yiwa alurar riga kafi a Vietnam. Daga cikin ma'aikatan kiwon lafiya 69 da suka gwada inganci ga SARS-CoV-2, 62 sun shiga cikin binciken asibiti, duk sun murmure. Ga guda 23 daga cikinsu, an sami cikakkun jerin kwayoyin halitta, kuma duk na bambance-bambancen Delta ne. "Yawan kwayar cuta na ci gaba da kamuwa da cutar Delta ya ninka sau 251 fiye da wadanda suka kamu da tsofaffin nau'ikan da aka gano tsakanin Maris-Afrilu 2020." |
| 8) Brown et al. | Barnstable, Massachusetts, Brown et al. An gano cewa a cikin shari'o'i 469 na COVID-19, kashi 74% an yi musu cikakkiyar allurar rigakafi, kuma "wadanda aka yi musu allurar sun fi yawan kwayar cutar a hanci fiye da wadanda ba a yi musu allurar ba." |
| 9) Hetemäli et al. | Rahoto kan a barkewar asibiti na asibiti a Finland, Hetemäli et al. ya lura cewa "an sami duka alamun alamun cutar da cututtukan asymptomatic a tsakanin ma'aikatan kiwon lafiya da aka yi wa alurar riga kafi, kuma watsa ta biyu ta faru daga waɗanda ke da alamun bayyanar cututtuka duk da amfani da kayan kariya na sirri." |
| 10) Shitrit et al. | a cikin wata barkewar asibiti bincike a Isra'ila, Shitrit et al. An lura da "babban watsawa na bambance-bambancen SARS-CoV-2 Delta tsakanin mutanen da aka yi wa allurar rigakafin sau biyu da masu rufe fuska." Sun kara da cewa "wannan yana nuna wasu raguwar rigakafi, duk da cewa har yanzu suna ba da kariya ga mutane ba tare da kamuwa da cuta ba." |
| 11) Rahoton Kula da rigakafin COVID-19 na Burtaniya na mako #42 | a cikin Rahoton Kula da rigakafin COVID-19 na Burtaniya na mako #42, an lura cewa akwai "ƙasa martanin N antibody akan lokaci" da "cewa matakan N antibody sun yi ƙasa da mutanen da suka kamu da kamuwa da cuta bayan allurai 2 na alluran rigakafi." Rahoton guda (Table 2, shafi na 13), ya nuna a cikin tsofaffin ƙungiyoyin da ke sama da 30, mutanen da aka yi wa allurar biyu suna da haɗarin kamuwa da cuta fiye da waɗanda ba a yi musu allurar ba, mai yiwuwa saboda ƙungiyar ta ƙarshe ta haɗa da ƙarin mutane waɗanda ke da ƙaƙƙarfan rigakafi na halitta daga cutar ta Covid. Sabanin haka, mutanen da aka yi wa alurar riga kafi suna da ƙananan haɗarin mutuwa fiye da waɗanda ba a yi musu allurar ba, a cikin kowane nau'in shekaru, wanda ke nuna cewa allurar rigakafin tana ba da ƙarin kariya daga mutuwa fiye da kamuwa da cuta. Duba kuma UK PHE ta ba da rahoton 43, 44, 45, 46 don irin wannan bayanai. |
| 12) Levin et al. | A cikin Isra'ila, Levin et al. "An gudanar da wani dogon nazari na tsawon watanni 6 wanda ya hada da ma'aikatan kiwon lafiya da aka yi wa alurar riga kafi da aka gwada kowane wata don kasancewar anti-spike IgG da kawar da kwayoyin cuta." Sun gano cewa "watanni shida bayan karbar kashi na biyu na allurar BNT162b2, martanin barkwanci ya ragu sosai, musamman a tsakanin maza, tsakanin mutane masu shekaru 65 ko sama da haka, da kuma tsakanin mutanen da ke da rigakafin rigakafi." |
| 13) Rosenberg et al. | A wani bincike daga jihar New York. Rosenberg et al. Ya ruwaito cewa "A cikin watan Mayu 3-Yuli 25, 2021, gabaɗayan ingantaccen maganin rigakafin shekaru a kan asibiti a New York yana da kwanciyar hankali 89.5% -95.1%). Gabaɗayan ingantaccen maganin rigakafin shekaru akan kamuwa da cuta ga duk manyan New York ya ragu daga 91.8% zuwa 75.0%." |
| 14) Suthar et al. | Suthar et al. Ya lura cewa "Bayananmu sun nuna babban raguwar martanin rigakafin mutum da rigakafin T cell zuwa SARS-CoV-2 da bambance-bambancen sa, a cikin watanni 6 bayan rigakafin na biyu tare da rigakafin BNT162b2." |
| 15) Nordstrom et al. | A wani bincike daga Jami'ar Umeå da ke Sweden. Nordstrom da al. Ya lura cewa "tasirin rigakafin BNT162b2 akan kamuwa da cuta ya ragu da sauri daga 92% (95% CI, 92-93, P <0 · 001) a ranar 15-30 zuwa 47% (95% CI, 39-55, P <0 · 001) a ranar 121-180 kuma ba a iya gano tasiri daga ranar (211%; 23% CI, -95-2, P=41·0)." |
| 16) Yahi et al. | Yahi et al. "A cikin yanayin bambance-bambancen Delta, kawar da ƙwayoyin rigakafi suna da alaƙa da sunadarin furotin, yayin da sauƙaƙe ƙwayoyin rigakafi suna nuna alaƙar haɓaka sosai. |
| 17) Goldberg et al. | (BNT162b2 Vaccine a Isra'ila) ya ba da rahoton cewa "kariya daga bambance-bambancen delta na SARS-CoV-2 ya ragu a cikin duk kungiyoyin shekaru 'yan watanni bayan samun kashi na biyu na rigakafin." |
| 18) Singanayagam et al. | yayi nazarin watsawa da motsin motsin ƙwayar cuta a cikin mutanen da aka yi wa alurar riga kafi da waɗanda ba a yi musu ba tare da kamuwa da cuta mai sauƙi a cikin al'umma. Sun gano cewa (a cikin abokan hulɗar al'umma 602 (wanda aka gano ta hanyar tsarin bin diddigin kwangilar Burtaniya) na 471 UK COVID-19 index lokuta an ɗauke su zuwa kimantawar watsawa da kamuwa da cutar ta COVID-19 a cikin binciken ƙungiyar lambobin sadarwa kuma sun ba da gudummawar samfuran 8145 na sama na numfashi daga samfuran yau da kullun har zuwa kwanaki 20 na kamuwa da cuta. Duk da haka, mutanen da ke da cikakkiyar rigakafin kamuwa da cuta suna da nauyin ƙwayar cuta mai kama da waɗanda ba a yi musu allurar ba kuma suna iya watsa kamuwa da cuta yadda ya kamata a cikin saitunan gida, gami da cikakkiyar allurar rigakafin. |
| 19) Kehner et al. | a NEJM, kwanan nan ya ba da rahoto game da sake bullar cutar SARS-CoV-2 a cikin ma'aikatan tsarin kiwon lafiya da aka yi wa allurar rigakafi. An fara yin allurar rigakafin mRNA a tsakiyar Disamba 2020; Ya zuwa Maris, kashi 76% na ma'aikata an yi musu cikakkiyar allurar riga-kafi, kuma a watan Yuli, kashi 87% ya karu zuwa kashi 2021%. Cututtuka sun ragu sosai a farkon Fabrairu 15…” daidai da ƙarshen wa'adin abin rufe fuska na California a ranar 1.617.2 ga Yuni da kuma saurin mamaye bambance-bambancen B.95 (delta) wanda ya fara bayyana a tsakiyar Afrilu kuma ya kai sama da kashi XNUMX% na keɓancewar UCSDH a ƙarshen Yuli, kamuwa da cuta ya karu cikin sauri, gami da kamuwa da cutar. "Sauyi mai ban mamaki a tasirin rigakafin daga Yuni zuwa Yuli na iya kasancewa saboda bullar bambance-bambancen delta da raguwar rigakafi akan lokaci." |
| 20) Juthani et al. | Juthani et al. ya nemi bayyana tasirin allurar rigakafi kan shigar da asibiti a cikin marasa lafiya da aka tabbatar da kamuwa da cutar SARS-CoV-2 ta amfani da bayanan duniyar da Tsarin Kiwon Lafiyar Yale New Haven ya tattara. "An yi la'akari da marasa lafiya da cikakken alurar riga kafi idan kashi na ƙarshe (ko dai kashi na biyu na BNT162b2 ko mRNA-1273, ko kashi na farko na Ad.26.COV2.S) an gudanar da shi aƙalla kwanaki 14 kafin bayyanar cututtuka ko gwajin PCR mai kyau na SARS-CoV-2. A cikin duka, mun gano marasa lafiya 969 da aka shigar da sabon asibiti na PCR tare da sabon gwajin lafiya na PCR. SARS-CoV-2”…Masu bincike sun ba da rahoton “yawan adadin marasa lafiya da ke da matsananciyar rashin lafiya a cikin waɗanda suka karɓi maganin BNT162b2 fiye da waɗanda suka karɓi mRNA-1273 ko Ad.26.COV2.S…” |
| 21) CDC | Wani bincike na baya-bayan nan da CDC ta buga ya ba da rahoton cewa yawancin (53%) na marasa lafiya da aka kwantar da su tare da cututtukan Covid-19-kamar an riga an yi musu cikakken allurar rigakafin RNA guda biyu. Tebu na 1 ya bayyana cewa a cikin manya 20,101 marasa lafiya da ke kwance a asibiti tare da Covid-19, 10,564 (53%) an yi musu cikakkiyar allurar rigakafin Pfizer ko Moderna (an bayyana alurar riga kafi da cewa sun karɓi daidai allurai 2 na mRNA na tushen COVID-19 ≥14 kwanaki kafin kwanan asibiti mafi ƙarancin kwanan watan da aka samu kwanan watan asibiti mafi ƙarancin kwanan wata. Sakamakon gwajin SARS-CoV-2 kafin asibiti ko ranar asibiti idan gwajin ya faru ne bayan shigar da shi kawai). Wannan ya nuna irin kalubalen da ake fuskanta na ci gaban Delta lokacin da aka yi musu allurar. |
| 22) Shekara, 2021 Tasirin rigakafin SARS-CoV-2 akan watsa bambance-bambancen Alpha & Delta. | Eyre, 2021 ya kalli tasirin rigakafin SARS-CoV-2 akan watsa bambance-bambancen Alpha & Delta. Sun ba da rahoton cewa "yayin da rigakafin har yanzu yana rage haɗarin kamuwa da cuta, irin wannan nau'in ƙwayar cuta a cikin masu allurar rigakafi da waɗanda ba a yi musu allurar rigakafin kamuwa da cutar ta Delta suna tambayar nawa allurar rigakafin ke hana yaduwar cutar… ya ƙi a cikin watanni 12 bayan allurar rigakafi na biyu… allurar rigakafin yana rage watsa Delta, amma ta ƙasa da bambance-bambancen Alpha. |
| 23) Levine-Tiefenbrun | Levine-Tiefenbrun, 2021 duba Nauyin kwayar cuta na Delta-bambance-bambancen SARS-CoV-2 ci gaban cututtukan cututtuka bayan rigakafin rigakafi da haɓakawa tare da BNT162b2, kuma ya ba da rahoton tasirin rage nauyin ƙwayar cuta yana raguwa tare da lokaci bayan allurar rigakafi, "yana raguwa sosai a cikin watanni 3 bayan rigakafin kuma yana ɓacewa sosai bayan kimanin watanni 6." |
| 24) Puranik, 2021 Kwatanta alluran rigakafin mRNA guda biyu masu inganci don COVID-19 yayin lokutan bambance-bambancen Alpha da Delta. | Puranik, 2021 ya dubi a Kwatanta alluran rigakafin mRNA guda biyu masu inganci don COVID-19 yayin lokutan bambance-bambancen Alpha da Delta., bayar da rahoto "A cikin Yuli, tasirin maganin rigakafi akan asibiti ya kasance mai girma (mRNA-1273: 81%, 95% CI: 33-96.3%; BNT162b2: 75%, 95% CI: 24-93.9%), amma tasiri akan kamuwa da cuta ya kasance ƙasa ga alluran biyu (mRNA: 1273% 76-95%; BNT58b87: 162%, 2% CI: 42-95%), tare da raguwa mai mahimmanci ga BNT13b62." |
| 25) Sadiya, 2021 Gwajin kawar da kwayar cutar ta kai tsaye a cikin marasa lafiya da abubuwan da aka yi wa allurar rigakafin 19A, 20B, 20I/501Y.V1 da 20H/501Y.V2 na SARS-CoV-2 | Saade, 2021 duba Gwajin kawar da kwayar cutar ta kai tsaye a cikin marasa lafiya da abubuwan da aka yi wa allurar rigakafin 19A, 20B, 20I/501Y.V1 da 20H/501Y.V2 na SARS-CoV-2, da kuma bayar da rahoto kamar yadda "Yi la'akari da ikon neutralizing kwayoyin rigakafi don hana kamuwa da kwayar cutar ta kwayar halitta, ta yin amfani da gwajin kwayar cutar kwayar cutar kwayar cutar tare da nau'i daban-daban [19A (na farko), 20B (B.1.1.241 lineage), 20I / 501Y.V1 (B.1.1.7 lineage), da 20H / 501Y.2.V1.351 da aka tattara daga layin layi na 19. Yawan jama'a: allurar rigakafin COVID-161-naive ma'aikatan kiwon lafiya (HCWs; Pfizer-BioNTech BNT2b6), watanni 19 bayan m COVID-19 HCWs, da kuma masu cutar COVID-20 masu mahimmanci… Binciken binciken yanzu shine rage martanin neutralizing da aka lura ga 501H/2Y.V162 tare da cikakken bambance-bambancen allurar rigakafi ta B2. nau'in daji da nau'in 20I / 501Y.V1." |
| 26) Kanada, 2021 Mahimman ragi a cikin rigakafi na ban dariya tsakanin ma'aikatan kiwon lafiya da mazauna gida watanni 6 bayan COVID-19 BNT162b2 rigakafin mRNA | Kanada, 2021 duba Mahimman ragi a cikin rigakafi na ban dariya tsakanin ma'aikatan kiwon lafiya da mazauna gida watanni 6 bayan COVID-19 BNT162b2 rigakafin mRNA, bayar da rahoton "Anti-karu, anti-RBD da neutralization matakan ragu fiye da 84% a kan watanni 6 'lokaci a duk kungiyoyin ba tare da la'akari da kafin SARS-CoV-2 kamuwa da cuta. A 6 months post-alurar riga kafi, 70% na kamuwa da cuta-naive NH mazauna sun neutralization titers a ko a kasa da ƙananan iyaka na ganowa idan aka kwatanta da 16% bayan da cikakken rigakafin duk matakan da aka nuna a cikin makonni 2. Musamman ma, waɗancan mazaunan NH masu kamuwa da cuta suna da ƙarancin rigakafi na farko bayan rigakafin nan da nan kuma sun nuna raguwa mafi girma bayan watanni 6. ” |
| 27) Isra'ila, 2021 Babban karatu na lalata titer na antibody bayan maganin BNT162b2 mRNA ko kamuwa da SARS-CoV-2 | Isra'ila, 2021 duba Babban karatu na lalata titer na antibody bayan maganin BNT162b2 mRNA ko kamuwa da SARS-CoV-2, kuma an ruwaito kamar yadda "Don tantance kinetics na SARS-CoV-2 IgG rigakafi bayan gudanar da allurai biyu na rigakafin BNT162b2, ko kamuwa da cutar SARS-CoV-2 a cikin mutanen da ba a yi musu allurar rigakafi ba… Batun 40% suna da matakan antibody a ƙasa da matakin sero-tabbatacce na <5 AU/ml, yayin da kawai 162% na marasa lafiya da ke fama da rashin lafiya sun kasance ƙasa da <2 AU/ml kofa bayan watanni 16.1 daga kamuwa da SARS-CoV-50. |
| 28) Shekarar 2020 Dogayen kinetics na ƙwayoyin rigakafi a cikin COVID-19 sun murmure marasa lafiya sama da watanni 14 | Eyran, 2020 yayi nazari Dogayen kinetics na ƙwayoyin rigakafi a cikin COVID-19 sun murmure marasa lafiya sama da watanni 14, kuma ya sami "mahimmanci mai saurin lalacewa a cikin alluran rigakafi idan aka kwatanta da marasa lafiya da aka dawo da su suna nuna cewa ƙwaƙwalwar ƙwayar cuta ta serological bayan kamuwa da cuta ta halitta ya fi ƙarfin idan aka kwatanta da alurar riga kafi. Bayananmu yana nuna bambance-bambance tsakanin ƙwaƙwalwar serological wanda ya haifar da kamuwa da cuta ta jiki vs. alurar riga kafi." |
| 29) Salvatore et al. | Salvatore et al. sun yi nazari kan yuwuwar watsa allurar rigakafi da marasa lafiya wadanda suka kamu da cutar SARS-CoV-2 Delta a wani gidan yari na tarayya, Yuli-Agusta 2021. Sun gano jimlar 978 samfuran mahalarta 95 ne suka bayar, “wanda 78 (82%) sun sami cikakkiyar allurar rigakafi kuma 17 (18%) bai kamata a yi la’akari da lafiyar jama’a ba. mutanen da aka yi wa alurar riga kafi waɗanda suka kamu da cutar ta SARS-CoV-2 don zama marasa kamuwa da cuta fiye da waɗanda ba a yi musu allurar ba. ” |
| 30) Andeweg et al. | Andeweg et al. bincikar 28,578 jerin SARS-CoV-2 samfurori daga mutane tare da sanannun matsayin rigakafi da aka samu ta hanyar gwajin al'umma na ƙasa a cikin Netherlands daga Maris zuwa Agusta 2021. Sun sami shaidar "ƙarin haɗarin kamuwa da cuta ta Beta (B.1.351), Gamma (P.1), ko Delta (B.1.617.2) bambance-bambancen bayan Alpha (B.1.1.7). An sami bambance-bambance tsakanin alluran rigakafi, duk da haka, tasirin ya fi girma a cikin kwanaki 14-59 na farko bayan cikakken rigakafin idan aka kwatanta da kwanaki 60 kuma ya fi tsayi. |
| 31) Di Fusco et al. | Di Fusco et al. gudanar da kimantawa na COVID-19 rigakafin ci gaban cututtuka a tsakanin marasa lafiya na rigakafi da aka yi cikakken alurar riga kafi tare da BNT162b2. "An yi gwajin rigakafin cutar ta COVID-19 a cikin cikakkiyar alurar riga kafi (≥14 kwanaki bayan kashi na biyu) daidaikun mutane IC (ICungiyar IC), ƙungiyoyin yanayin IC guda 2 masu keɓancewa da juna, da ƙungiyar marasa IC." Sun gano cewa "na 12 mutane ≥1,277,747 shekaru masu shekaru da suka karbi 16 BNT2b162 allurai, 2 (225,796%) an gano su a matsayin IC (tsakiyar shekaru: 17.7 shekaru; 58% mace). Mafi yawan yanayin IC sun kasance m rashin lafiya (56.3%), cututtuka na koda, cututtuka na koda, 32.0%). (19.5%) a cikin cikakken allurar rigakafin IC da wadanda ba IC ba, an lura da jimlar 16.7 na ci gaba da kamuwa da cuta a lokacin binciken;N = 374) na duk cututtuka masu tasowa, 59.7% (N = 74) na duk asibiti, da 100% (N = 2) na mutuwar marasa lafiya. Matsakaicin kamuwa da cututtukan ci gaba shine sau 3 mafi girma a cikin ƙungiyar IC idan aka kwatanta da ƙungiyar da ba ta IC ba (N = 374 (0.18%) N = 604 [0.06%]; Adadin abubuwan da ba a daidaita su ba sun kasance 0.89 da 0.34 a cikin shekaru 100 na mutum, bi da bi. |
| 32) Mallapaty (NATURE) | (NATURE) ta ruwaito cewa tasirin kariya na allurar rigakafi idan kun riga kun kamu da cutar “kananan kadan ne, kuma yana raguwa sosai a cikin watanni uku bayan samun harbi na biyu.” Mallapaty ya kara da cewa abin da muke gargadin al'ummar kiwon lafiyar jama'a wanda shine mutanen da suka kamu da cutar ta Delta suna da nau'ikan nau'ikan kwayoyin cutar kwayar cuta a cikin hancinsu "ba tare da la'akari da ko an riga an yi musu allurar ba, yana mai nuna cewa wadanda aka yi musu allurar da wadanda ba a yi musu allurar ba za su iya kamuwa da cutar." Mallapaty ya ba da rahoto game da bayanan gwaji daga 139,164 abokan hulɗa na mutane 95,716 da suka kamu da SARS-CoV-2 tsakanin Janairu da Agusta 2021 a Burtaniya, kuma a lokacin da bambance-bambancen Alpha da Delta ke fafatawa don mamayewa. Sakamakon binciken shine "duk da cewa allurar rigakafin sun ba da kariya daga kamuwa da cuta da kuma yadawa, Delta ta rage tasirin.nasara'Cutar Delta kusan sau biyu tana iya kamuwa da cutar kamar wanda ya kamu da Alpha. Kuma hakan ya kasance mafi girman haɗarin kamuwa da kamuwa da cuta daga Delta fiye da wanda Alpha ke haifarwa. ” |
| 33) Chia et al. | Chia et al. ya ruwaito cewa ƙimar sake zagayowar PCR (Ct) sun kasance "daidai tsakanin duka ƙungiyoyin alurar riga kafi da marasa alurar riga kafi a ganewar asali, amma nauyin ƙwayar cuta ya ragu da sauri a cikin mutanen da aka yi wa alurar riga kafi. Tun da farko, an lura da ingantaccen haɓakar ƙwayoyin rigakafin ƙwayoyin cuta a cikin marasa lafiya da aka yi wa alurar riga kafi, duk da haka, waɗannan titers sun kasance ƙasa da ƙasa da B.1.617.2 idan aka kwatanta da allurar daji. |
| 34) Wilhelm et al. | Wilhelm et al. an ba da rahoto game da raguwar bambance-bambancen SARS-CoV-2 omicron ta hanyar rigakafin sera da ƙwayoyin rigakafin monoclonal. "a vitro Binciken da aka yi amfani da ingantattun bambance-bambancen SARS-CoV-2 sun nuna cewa sabanin bambance-bambancen Delta da ke yawo a halin yanzu, tasirin tasirin maganin rigakafin rigakafin rigakafin cutar Omicron ya ragu sosai yana nuna rigakafi ta hanyar T-cell a matsayin muhimmin shinge don hana mummunan COVID-19. ” |
| 35) Rahoton CDC | CDC ta ba da rahoto game da cikakkun bayanai game da shari'o'i 43 na COVID-19 da aka danganta ga bambance-bambancen Omicron. Sun gano cewa "34 (79%) sun faru a cikin mutanen da suka kammala jerin farko na maganin FDA-izni ko amincewa da maganin COVID-19 kwanaki 14 kafin bayyanar alama ko samun ingantaccen sakamakon gwajin SARS-CoV-2." |
| 36) Dejnirattisai et al. | Dejnirattisai et al. An gabatar da titin kawar da kai a kan bambance-bambancen SARS-CoV-2 Omicron, kuma sun gwada shi dangane da kawar da bambance-bambancen Victoria, Beta da Delta. Sun ba da rahoton raguwar raguwar "titres na tsaka-tsaki a cikin masu karɓar duka AZD1222 da BNT16b2 kwasa-kwasan farko, tare da shaidar wasu masu karɓa sun kasa kawar da komai." |
| 37) Cele et al. | Cele et al. An tantance ko bambance-bambancen Omicron ya tsere wa kawar da kwayar cutar “wanda allurar Pfizer BNT162b2 mRNA ta haifar a cikin mutanen da aka yi wa allurar rigakafi kawai ko kuma aka yi musu allurar rigakafi kuma a baya sun kamu da cutar.” Sun ba da rahoton cewa bambance-bambancen Omicron "har yanzu yana buƙatar mai karɓar ACE2 don kamuwa da cuta amma yana da tserewa da yawa na Pfizer ya haifar da neutralization." |
| 38) Holm Hansen et al. | Nazarin Holm Hansen et al.'s Denmark ya duba tasirin rigakafin rigakafin kamuwa da cutar SARS-CoV-2 tare da bambance-bambancen Omicron ko Delta bin kashi biyu ko haɓaka BNT162b2 ko mRNA-1273 jerin rigakafin. An ba da rahoton wani mahimmin binciken kamar yadda "VE a kan Omicron ya kasance 55.2% da farko ya biyo bayan allurar farko na BNT162b2, amma ya ragu da sauri bayan haka. Ko da yake an kiyasta tare da ƙarancin daidaito, VE a kan Omicron bayan rigakafin mRNA-1273 na farko ma yana nuna raguwar kariya cikin sauri. Ma'ana, maganin da ya gaza a kan Delta ya fi muni ga Omicron. Tebur da adadi na ƙasa suna zana hoto mai ban tsoro. Duba inda koren ɗigon (Omicron bambance-bambancen) a cikin layi na tsaye (blue shine Delta) da gefuna 2 na sanduna ( leɓuna na sama da na ƙasa ) kwanaki 91 don Omicron (watanni 3). Dukansu Pfizer da Moderna suna nuna rashin tasiri ga Omicron a cikin kwanaki 31 (dukansu suna ƙasa da 'layin babu tasiri' ko '0'). Teburin kwatancen ya ma fi ɓarna saboda yana nuna ƙarancin tasirin allurar rigakafin da ke akwai ga Omicron. Misali, a cikin kwanaki 1-30, Pfizer ya nuna tasiri na 55.2% don Omicron da 86.7% na Delta, kuma a daidai wannan lokacin, Moderna ya nuna tasirin 36.7% na Omicron da 88.2% na Delta. |
| 39) Hukumar Tsaron Lafiya ta Burtaniya | Rahoton Burtaniya ya nuna cewa masu haɓakawa suna ba da kariya daga alamun COVID-19 da Omicron ya haifar na kusan makonni 10; da Hukumar Tsaron Lafiya ta Burtaniya An ba da rahoton kariya daga alamun COVID-19 da bambance-bambancen ya haifar ya ragu daga kashi 70% zuwa 45% biyo bayan mai haɓaka Pfizer ga waɗanda aka yi wa allurar rigakafin da aka yi da farko tare da harbin da Pfizer ya haɓaka tare da BioNTech. Musamman rahoto ta hanyar Hukumar Tsaron Lafiya ta Burtaniya Daga cikin wadanda suka karbi kwas na farko na AstraZeneca, tasirin rigakafin ya kasance kusan 60% 2 zuwa 4 makonni bayan ko dai Pfizer ko Moderna booster, sannan ya ragu zuwa 35% tare da Pfizer booster da 45% tare da haɓakar Moderna ta makonni 10 bayan haɓakar. 70-da makonni kuma ya zauna kusan 45 zuwa 10% bayan haɓakar Moderna har zuwa makonni 70 bayan haɓakawa. |
| 40) Buchan et al. | Buchan et al. sun yi amfani da ƙirar gwaji mara kyau don tantance tasirin allurar rigakafin OMICRON ko bambance-bambancen DELTA (ba tare da la'akari da alamun cutar ko tsananin ba) a lokacin Nuwamba 22 da Disamba 19, 2021. Sun haɗa da mutanen da suka karɓi aƙalla alluran rigakafin COVID-2 na 19 (tare da aƙalla 1 mRNA maganin alurar riga kafi don farkon farko) kuma sun yi amfani da ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙima na tsawon lokaci guda biyu. latest dose." Sun haɗa da shari'o'in 3,442 Omicron-tabbatacce, shari'o'in 9,201 Delta-tabbatacce, da kuma 471,545 marasa ƙarfi na gwaji. Bayan allurai 2, "Tasirin rigakafin rigakafin kamuwa da cutar Delta ya ragu akai-akai akan lokaci amma ya murmure zuwa 93% (95% CI, 92-94%) ≥7 kwanaki bayan karbar maganin mRNA na kashi na uku. Sabanin haka, karbar allurai 2 na rigakafin COVID-19 bai kasance mai karewa daga Omicron ba. ≥37 kwanaki bayan karbar maganin mRNA na kashi na uku." |
| 41) Kiwon Lafiyar Jama'a Scotland COVID-19 & Rahoton Ƙididdiga na Winter | Kiwon Lafiyar Jama'a Scotland COVID-19 & Rahoton Ƙididdiga na Winter (Ranar Bugawa: 19 Janairu 2022) ya ba da bayanai masu ban mamaki a shafi na 38 (yawan shari'a), shafi na 44 (a asibiti), da shafi na 50 (mutuwar), wanda ke nuna cewa allurar rigakafin ta gaza Delta amma da gaske, tana gaza omicron. Na 2nd bayanan inoculation yana da matukar damuwa. Tebur 14 daidaitattun shari'o'in shari'o'in shekaru yana da matukar damuwa don ya nuna a cikin makonni da yawa na binciken cewa a cikin kowane kashi (1 vs 2 vs 3 inoculations booster) cewa masu maganin alurar riga kafi sun fi kamuwa da cutar fiye da wadanda ba a yi musu ba, tare da 2.nd Ana ƙara ƙarar kashi mai ban tsoro (duba layuka masu launin toka). Matsakaicin shekarun shigar da asibiti na asibiti yana da girma da ban mamaki bayan 2nd inoculation (a kan marasa alurar riga kafi) a lokacin Janairu 2022. Duban tebur 16 da ke bayar da rahoton adadin adadin wadanda aka tabbatar da COVID-19 da ke da alaƙa ta hanyar alurar riga kafi, mun sake lura da hauhawar mutuwa a 2ndallurar rigakafi. Wannan bayanan yana nuna mana cewa maganin yana da alaƙa da kamuwa da cuta kuma baya aiki da kyau akan omicron kuma kariya ta iyakance, tana raguwa cikin sauri. |
| 42) Rahoton sa ido kan rigakafin COVID-19 na Burtaniya Mako 3, 20 ga Janairu 2022 | Rahoton sa ido kan rigakafin COVID-19 na Burtaniya Makon 3, 20 ga Janairu 2022, ya haifar da matukar damuwa game da gazawar allurar rigakafin a Delta (wanda a yanzu ana maye gurbinsa da omicron don rinjaye) da omicron. Idan muka kalli tebur 9, shafi na 34 (Lambobin COVID-19 ta yanayin alurar riga kafi tsakanin sati 51 2021 da sati 2 2022), zamu ga manyan lambobi na 2nd kuma 3rd alluran rigakafi. Muhimmiyar tebur a shafi na 38, Hoto na 12 (Rashin daidaitawa na kamuwa da cutar COVID-19, asibiti da mutuwa a cikin alurar riga kafi da yawan alurar riga kafi) yana nuna mana ci gaba a cikin bayanan Burtaniya a cikin watanni 2 zuwa 3 zuwa 4 da suka gabata, tare da rahoton yanzu yana nuna cewa mutanen da ke karɓar 3rd inoculation (ƙarfafa) a cikin haɗarin kamuwa da cuta / lokuta fiye da waɗanda ba a yi musu rigakafi ba (shekaru 30 da sama da shekaru). |
| 43) Rahoton Kula da Lafiyar Jama'a na Burtaniya | A cikin rahotannin sa ido kan Kiwon Lafiyar Jama'a na Burtaniya kwanan nan Week 9, Week 8, da kuma mako na 7 (Rahoton kula da rigakafin COVID-19 na Burtaniya Makon 7 17 ga Fabrairu 2022), mako na 6 (Rahoton sa ido kan rigakafin COVID-19 Makon 6 10 ga Fabrairu 2022da mako 5 don 2022 (Rahoton sa ido kan rigakafin COVID-19 Makon 5 3 ga Fabrairu 2022) da kuma rahotannin da aka tara a shekarar 2021 tun bayan da aka fitar da allurar rigakafin, mun ga cewa wadanda aka yi wa allurar suna cikin hadarin kamuwa da cutar musamman ga masu shekaru sama da 18, da kuma asibiti har ma da mutuwa. An yi wa wannan alama musamman ga waɗanda ke karɓar allurar rigakafi sau biyu. Ana samun ƙarin haɗarin mutuwa ga waɗanda aka yi wa allurar sau uku musamman yayin da shekaru ke ƙaruwa. Irin wannan tsari yana fitowa a cikin bayanan Scotland. |
| 44.) Regev-Yochay et al. | Regev-Yochay et al. a Isra'ila duba (kwanan bugu Maris 16th 2022) rigakafin rigakafi da amincin kashi na huɗu (4th) na ko dai BNT162b2 (Pfizer-BioNTech) ko mRNA-1273 (Moderna) ana gudanar da watanni 4 bayan kashi na uku a cikin jerin nau'o'in BNT162b2 guda uku). Wannan shi ne buɗaɗɗen lakabin, binciken asibiti mara izini wanda ke kimanta 4th kashi cikin sharuddan buƙata fiye da 3rd kashi. Daga cikin 'ma'aikatan kiwon lafiya masu cancanta 1050 da suka yi rajista a cikin Sheba HCW COVID-19 Cohort, 154 sun sami kashi na huɗu na BNT162b2 kuma, mako 1 bayan haka, 120 sun karɓi mRNA-1273. Ga kowane ɗan takara, an zaɓi sarrafawa guda biyu masu dacewa da shekaru daga ragowar mahalarta masu cancanta.
Masu bincike sun ci gaba da ba da rahoton cewa 'gaba ɗaya, 25.0% na mahalarta a cikin rukunin kulawa sun kamu da bambancin omicron, idan aka kwatanta da 18.3% na mahalarta a cikin rukunin BNT162b2 da 20.7% na waɗanda ke cikin rukunin mRNA-1273. Ingancin allurar rigakafin kowane kamuwa da SARS-CoV-2 shine 30% (95% tazarar amincewa [CI], -9 zuwa 55) don BNT162b2 da 11% (95% CI, -43 zuwa 44) don mRNA-1273… yawancin mahalarta masu kamuwa da cutar sun kasance masu iya kamuwa da cuta, tare da ɗaukar nauyi mai ƙarfi na ƙwayoyin cuta. ≤25)'. Sakamako sun nuna cewa ana samun mafi girman immunogenicity na allurar mRNA bayan allurai uku. Musamman ma, masu bincike 'sun lura da ƙarancin ingancin allurar rigakafin kamuwa da cuta a cikin ma'aikatan kiwon lafiya, da kuma babban nauyin ƙwayar cuta wanda ke nuna cewa waɗanda suka kamu da cutar suna da kamuwa da cuta. Don haka, allurar rigakafi na huɗu na ma'aikatan kiwon lafiya masu lafiya na iya samun fa'idodi kaɗan kawai'. |
| 45.) Andrews et al. | Andrews et al. ya yi amfani da ƙirar gwaji-mara kyau don ƙididdige tasirin rigakafin rigakafin cututtukan da ke haifar da bambance-bambancen omicron da delta (B.1.617.2) a Ingila. "An ƙididdige tasirin rigakafin bayan rigakafin farko tare da allurai biyu na BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), ko mRNA-1273 (Moderna) da kuma bayan ƙarar kashi na BNT162b2, ChAdOx1 nCoVRNA-19." Sakamakon ya nuna cewa alluran rigakafi tare da allurai biyu na ChAdOx1273 nCoV-1 ko BNT19b162 rigakafin ya ba da ƙayyadaddun kariya daga cututtukan alamomin da ke haifar da bambance-bambancen omicron. "A BNT2b162 ko mRNA-2 mai ƙarfafawa bayan ko dai ChAdOx1273 nCoV-1 ko BNT19b162 matakin farko ya ƙara kariyar sosai, amma wannan kariyar ta ragu cikin lokaci." |
| 46) Hoffmann et al. | Hoffmann et al. An buga a mujallar CELL cewa OMICRON spike protein (antigen) ya nisanta kansa daga maganin rigakafi daga “masu jinya ko kuma mutanen da aka yi musu allurar rigakafin BioNTech-Pfizer (BNT162b2) tare da inganci mai ninki 12 zuwa 44 fiye da girman bambance-bambancen Delta. (Astra Zeneca-Oxford)/BNT1b162 rigakafi ko allurar rigakafi tare da allurai uku na BNT2b162 ya fi inganci, amma har yanzu karu na Omicron ya guje wa neutralization da inganci fiye da girman Delta. Gabaɗaya, sakamakon ya nuna cewa yawancin ƙwayoyin rigakafin warkewa ba za su yi tasiri a kan bambance-bambancen Omicron ba kuma cikin firgita, cewa alluran rigakafin sau biyu tare da BNT2b162 (Pfizer) na iya “ba da isasshiyar kariya daga mummunar cutar da wannan bambance-bambancen ta haifar.” |
| 47) Bar-on et al. | Bar-on et al. wanda aka buga a NEJM a ƙarƙashin taken: Kariya ta kashi na huɗu na BNT162b2 akan Omicron a cikin Isra'ila. Sun kimanta bayanan Ma'aikatar Lafiya ta Isra'ila tare da tattara bayanai akan mutane 1,252,331 waɗanda shekarunsu suka wuce 60 ko sama da haka kuma sun cancanci kashi na huɗu a cikin lokacin da bambance-bambancen B.1.1.529 (omicron) na SARS-CoV-2 ya kasance mafi rinjaye (Janairu 10 zuwa Maris 2, 2022). Binciken ya mayar da hankali kan adadin da aka tabbatar da kamuwa da cuta da kuma Covid-19 mai tsanani a matsayin aikin lokaci na farawa daga kwanaki 8 bayan karɓar kashi na huɗu (rukunin kashi huɗu) idan aka kwatanta da na mutanen da suka karɓi allurai uku kawai (rukunin kashi uku) da kuma tsakanin mutanen da suka karɓi kashi na huɗu 3 zuwa 7 kwanaki a baya (ƙungiyar kula da ciki). Sun yi amfani da ƙirar ƙira-Poisson regression kuma tare da daidaitawa ga masu ruɗewa, an daidaita su don shekaru, jima'i, ƙungiyar alƙaluma, da ranar kalanda.
Abubuwan da aka gano sun nuna gazawar 4th kashi, shine kamar haka: “Kwantanta adadin adadin akan lokaci tun daga kashi na huɗu (Figure 2) yana ba da shawarar cewa kariyar da aka tabbatar da kamuwa da cuta tare da bambance-bambancen omicron ya kai matsakaicin a cikin mako na huɗu bayan allurar rigakafi, bayan haka adadin adadin ya ragu zuwa kusan 1.1 ta mako na takwas; Wadannan binciken sun nuna cewa kariyar da aka tabbatar da kamuwa da cuta ta ragu da sauri…Madaidaicin adadin kamuwa da cuta a cikin mako na takwas bayan kashi na hudu ya yi kama da na kungiyoyin kulawa; Matsakaicin adadin ga rukunin kashi uku idan aka kwatanta da rukunin kashi huɗu shine 1.1 (95% CI, 1.0 zuwa 1.2), kuma ƙimar ƙimar ƙungiyar kulawa ta ciki idan aka kwatanta da rukunin kashi huɗu kawai 1.0 (95% CI, 0.9 zuwa 1.1)." Waɗannan binciken ba su nuna wani bambanci ba.
Har ila yau, muna da damuwa game da hanyoyin kamar yadda ya bayyana a fili ba za su iya ko ba su iya sarrafawa don matsawa masu rikitarwa (hargitsi) masu canji waɗanda zasu iya tasiri ga binciken. Wannan na iya haifar da sau da yawa zuwa overestimation (ko rashin kima) na magani sakamako. Misali, shin sun sarrafa don kamuwa da cuta kafin kamuwa da cuta, shin sun sarrafa don amfani da magungunan da wuri, shin sun daidaita don bambance-bambancen halaye a cikin rukunin kashi na 4, ko yanayin da suka gabata, ko jiyya daban-daban da sauransu. kwanaki na farko bayan allurar rigakafi, kuma, mutum zai yi tsammanin cewa nuna son kai saboda sauye-sauyen halaye, kamar yanayin yin ƴan gwaje-gwaje bayan allurar, ya fi bayyana jim kaɗan bayan an karɓi maganin. |
| 48) Dorewa na rigakafin BNT162b2 akan asibiti da shigar da sashen gaggawa saboda bambance-bambancen omicron da delta a cikin babban tsarin kiwon lafiya a cikin Amurka: nazarin gwajin-kore, Tartof, 2022. | Masu bincike sun kimanta tasiri da dorewa na nau'i biyu da uku na maganin rigakafi na BNT162b2 (Pfizer-BioNTech) mRNA akan asibiti da shigar da sashen gaggawa saboda delta (B.1.617.2) da kuma omicron bambance-bambancen; nazari na sarrafa shari'a tare da ƙirar gwaji-mara kyau, nazari bayanan lafiyar lantarki na mambobi na Kaiser Permanente Southern California (KPSC), babban tsarin kiwon lafiya mai haɗaka a California, Amurka, daga Dec 1, 2021, zuwa Feb 6, 2022; "An yi nazari na asibiti na 11 123 ko kuma shiga sashen gaggawa. A cikin gyare-gyaren da aka gyara, tasiri na nau'i biyu na maganin rigakafi na BNT162b2 game da bambancin omicron shine 41% (95% CI 21-55) a kan shigar da asibiti da kuma 31% (16-43) game da shigar da sashen gaggawa bayan watanni na biyu ko fiye" Masu binciken sun kuma ba da rahoton cewa "watanni 9 bayan karbar kashi na uku, raguwa ya bayyana a fili game da sakamakon SARS-CoV-3 saboda bambancin omicron, gami da shigar da asibiti." |
| 49) Laith J. Abu-Raddad et al. (Mayu, 2022): | "Tasirin Tallafin rigakafin mRNA akan Cutar SARS-CoV-2 Omicron a Qatar"; kamar yadda muke gani, maganin ya gaza, VE shine <50% (kofar da ake buƙata) da mutuwar '0'; "Nazarin ƙungiyar guda biyu sun daidaita don tantance tasirin rigakafin haɓaka, idan aka kwatanta da na jerin kashi biyu na farko kawai, game da kamuwa da cuta ta SARS-CoV-2 da cutar Covid-19 da ke da alaƙa da asibiti da mutuwa yayin babban bala'in cututtukan omicron daga ranar 19 ga Disamba, 2021, har zuwa 26 ga Janairu, 2022 tare da haɓakar kamuwa da cutar. Samfurin koma bayan hatsarori-daidaitacce." Kamar yadda muke gani, maganin ya gaza, VE shine <50% (kofar da ake buƙata) da '0' mutuwar.
Abubuwan da aka gano sune kamar haka don nuna cewa allurar rigakafin ba su kai ga 50% na tasiri ba:
Ingancin BNT162b2 Booster akan Bambancin Omicron
"Kimanin tasiri na BNT162b2 booster (Pfizer) game da kamuwa da cuta na omicron, idan aka kwatanta da na jerin kashi biyu na farko, shine 49.4% (95% CI, 47.1 zuwa 51.6)."
Ingancin mRNA-1273 Mai haɓakawa akan Bambancin Omicron
"Kimanin tasiri na mRNA-1273 booster (Moderna), idan aka kwatanta da na jerin kashi biyu na farko, shine 47.3% (95% CI, 40.7 zuwa 53.3)."
ƙarin ƙididdiga
"Don nazarin rigakafin BNT162b2, tare da fara bibiyar a ranar 15th bayan rigakafin haɓakar haɓakar rigakafin, kimanta tasirin mai haɓakawa game da kamuwa da cututtukan omicron, idan aka kwatanta da na jerin farko na kashi biyu, ya kasance 49.9% (95% CI, 47.6 zuwa 52.2) (S2 zuwa 4) (S1273 zuwa 52.0). Alurar riga kafi shine 95% (45.1% CI, 57.9 zuwa XNUMX).
Ƙididdigar ingantaccen tasirin maganin rigakafi na BNT162b2 game da kamuwa da cuta na omicron na alama, idan aka kwatanta da na jerin kashi biyu na farko, shine 38.0% (95% CI, 28.8 zuwa 46.0) a cikin mutanen da suka karɓi haɓakar watanni 8 ko ƙasa da haka bayan kashi na biyu da 50.5% (95% CI) zuwa 48.2 fiye da waɗanda suka karɓi fiye da watanni 52.8. bayan kashi na biyu. Matsakaicin madaidaicin tasirin maganin mRNA-8 shine 1273% (41.5% CI, 95 zuwa 32.3) da 49.5% (56.8% CI, 95 zuwa 47.0).” |
| 50) Fleming-Dutra et al. | Fleming-Dutra et al. yayi nazari akan Ƙungiyar Kafin BNT162b2 Rigakafin COVID-19 Tare da Alamun Cutar Cutar SARS-CoV-2 a cikin Yara da Matasa A Yayin Rikon Omicron. Sun yi amfani da wani gwaji mara kyau, binciken kula da shari'a da aka gudanar daga Disamba 2021 zuwa Fabrairu 2022 yayin fifikon Omicron wanda ya haɗa da gwaje-gwaje 121 952 daga shafuka a duk faɗin Amurka, an kiyasta tasirin maganin rigakafin kamuwa da kamuwa da cuta ga yara masu shekaru 5 zuwa 11 ya kasance 60.1% 2 zuwa 4 makonni bayan kashi 2 da kashi 28.9 cikin 2. zuwa shekaru 2, kiyasin tasirin rigakafin shine 12% 15 zuwa 59.5 makonni bayan kashi 2 da 4% a cikin watan 2 (duba Hoto 16.6). Sun kammala da cewa "a tsakanin yara da matasa, kiyasin tasirin allurar rigakafi na 2 allurai na BNT2b2 game da kamuwa da cuta ya ragu da sauri". Muna ganin VE yana raguwa a ƙasa 162 a kusan watanni 2. |
| 51) Lassaunière et al: | Lassaunière et al: "Ayyukan Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant (BA.1) 1 zuwa 18 Makonni Bayan Na Biyu da Na Uku Allurai na BNT162b2 mRNA Vaccine"; "Bincikenmu ya sami raguwa da sauri a cikin takamaiman maganin Omicron wanda ke kawar da titers kawai bayan 'yan makonni bayan kashi na biyu da na uku na BNT162b2… na BNT162b2 na wucin gadi ne kuma ƙarin allurai masu ƙarfafawa na iya zama dole, musamman a cikin tsofaffi; duk da haka, rigakafin ƙwayoyin cuta na T-cell na iya ba da kariya daga asibiti da mutuwa. |
| 52) Kariya da Rarraba Tsarin Halitta da Haɓaka ga SARS-CoV-2 | “Yawancin kamuwa da cutar SARS-CoV-2 a cikin kwana 100,000 na cikin haɗari (daidaita adadin) ya karu tare da lokacin da ya wuce tun lokacin da aka yi allurar rigakafin BNT162b2 ko kuma tun bayan kamuwa da cutar a baya. A baya can cikin mutanen da suka sami alluran rigakafi guda daya bayan kamuwa da cutar a baya, an daidaita adadin wadanda aka yi wa allurar kasa da watanni 10.5 a baya amma ya karu zuwa 4 daga cikin wadanda aka yi wa allurar akalla watanni 6 a baya wadanda suka sami allurai biyu na alluran rigakafin zuwa watanni 30.2 a baya. wanda aka yiwa allurar akalla watanni 1 a baya.
Daga cikin mutanen da suka kamu da cutar ta SARS-CoV-2 a baya (ba tare da la'akari da ko sun karɓi kowane nau'in rigakafin ko kuma sun karɓi kashi ɗaya kafin ko bayan kamuwa da cuta), kariya daga sake kamuwa da cuta ta ragu yayin da lokacin ya ƙaru tun daga taron bayar da rigakafi na ƙarshe; duk da haka, wannan kariyar ta fi wanda aka bayar bayan lokaci guda ya wuce tun lokacin da aka sami kashi na biyu na rigakafin a tsakanin mutanen da ba su kamu da cutar a baya ba. Kashi ɗaya na allurar rigakafi bayan kamuwa da cuta ya ƙarfafa kariya daga sake kamuwa da cuta." |
| 53) CDC da raguwa 2-Kashi da 3-Kashi Tasirin MRNA Alurar rigakafin COVID-19-Haɗin Sashen Gaggawa da Haɗuwa da Kulawa da Kulawa da Asibiti Tsakanin Manya A Lokacin Zamanin Delta da Omicron Variant Predominance - VISION Network, Jihohi 10, Agusta 2021-Janairu, 2022.: | "A lokacin Omicron-mafi rinjaye, VE a kan COVID-19-abokan hulɗar ED / UC ya kasance ƙasa da ƙasa idan aka kwatanta da wancan a lokacin lokacin mafi rinjaye na Delta kuma ya ragu bayan kashi na biyu, daga 69% a cikin watanni 2 na alurar riga kafi zuwa 37% a ≥5 watanni bayan alurar riga kafi (p <0.001) tare da kashi 87 na allurar rigakafi a cikin kashi na uku. A cikin watanni 2 da suka gabata, VE bayan allurai 3 sun ƙi zuwa 66% a cikin waɗanda aka yi wa alurar riga kafi watanni 4-5 da suka gabata da 31% a cikin waɗanda aka yi wa alurar riga kafi watanni 5 da suka gabata… 241,204, kiyasi na VE game da gwajin da aka tabbatar da COVID-93,408 sun yi ƙasa a lokacin Omicron-mafi rinjaye fiye da lokacin mafi rinjaye na Delta, bayan lissafin duka adadin alluran rigakafin da aka karɓa da kuma lokaci tun lokacin rigakafin. A cikin lokuta biyu, VE bayan karɓar kashi na uku ya kasance koyaushe sama da VE bayan kashi na biyu; duk da haka, VE ya ragu tare da karuwar lokaci tun lokacin alurar riga kafi." |
| 54) Sakamako mai tsanani na COVID-19 bayan cikakken allurar rigakafi na jadawalin farko da masu haɓakawa na farko: haɗaɗɗen bincike na nazarin ƙungiyar ƙasa da ƙasa na mutane miliyan 30 a Ingila, Arewacin Ireland, Scotland, da Wales, Agrawal et al., Oktoba, 2022 | "An sami ƙarin haɗarin sakamakon COVID-19 mai tsanani makonni 10 bayan kammala matakan farko na BNT162b2 ko ChAdOx1 nCoV-19 (≥20 makonni) vs makonni 3-9; aRR 4 · 55 [95% CI 4·16–4·99]). Mutanen da ke da adadi mai yawa na cututtuka (≥5 comorbidities vs babu; 7 · 98 [7 · 73 – 8 · 24], waɗanda suka girmi (shekaru ≥80 shekaru vs shekaru 18-49; 8 · 12 [7 · 89-8 · 35]), wanda ke da BMI mafi girma (≥40) vs 18·5–24·9; 1 · 75 [1 · 69–1 · 82]), ko kuma wadanda suke maza (namiji vs mace; 1 · 19 [1 · 17 – 1 · 21]) kuma suna da alaƙa da haɓakar haɗarin sakamakon COVID-19 mai tsanani. ”
Wannan bincike na tushen yawan jama'a na Burtaniya sama da miliyan 16 a cikin Ingila, Arewacin Ireland, Scotland, da Wales ya gano cewa, bayan haɓakar rigakafin farko, tsofaffi, waɗanda ke da yawan kamuwa da cuta, da waɗanda ke da wasu yanayin rashin lafiya suna kasancewa cikin haɗarin asibiti da ke da alaƙa da COVID-19. Waɗannan binciken suna da matsala sosai ga masu ba da shawarar rigakafin. Alurar rigakafin kwayar halittar COVID ta kasa, ba ta hana haihuwa ba, ba ta tsaka-tsaki, ba ta kare manyan hanyoyin iska (ba ta hana kamuwa da cuta ko yadawa) kuma ba ta da kyau ko kuma ta kare ƙananan huhu daga mummunan cuta. |
| 55) Ɗaukar kashi na farko da na biyu na ChAdOx1 da BNT162b2 COVID-19 alluran rigakafin: hadaddiyar gwajin gwaji na mutane miliyan 12.9 a Ingila, Arewacin Ireland, Scotland da Wales, Karfe, 2022 | "Don Doses 1 da 2 na ChAdOx1 da Dose 1 na BNT162b2, VE / rVE ya kai sifili ta kusan Kwanaki 60-80 sannan ya tafi mara kyau. A ranar 70, VE / rVE ya kasance -25% (95% CI: -80 zuwa 14) da 10% (95% zuwa CI: -32) ChAdOx39, bi da bi, da 1% (2% CI: 1 zuwa 42) da 95% (9% CI: 64 zuwa 53) don Doses 95 da 26 na BNT70b1, bi da bi, don Kashi 2 na BNT162b2 sun kasance sama da sifili% bayan 2 zuwa 162% kwanakin biyo baya.
An sami shaida mai ƙarfi na raguwa a cikin VE/rVE don Doses 1 da 2 na ChAdOx1, da kuma kashi 1 na BNT162b2."
Hukumomin kiwon lafiyar jama'a ba su san wannan binciken ba. A hakika, Daraktan CDC Rochelle Walensky ya ce allurar rigakafin Covid suna aiki "na musamman da kyau" game da rashin lafiya da mutuwa, amma "abin da ba za su iya ba shi ne hana yaduwa."
Abin da waɗannan binciken ke nunawa, shine, alluran rigakafi na da mahimmanci don rage cututtuka masu tsanani da mutuwa, amma ba za su iya hana cutar yaduwa ba kuma a ƙarshe ta kama yawancin mu. Wato yayin da alluran rigakafin ke ba da fa'ida ga mutum ɗaya ga allurar, musamman ga tsofaffi masu haɗarin gaske, amfanin al'umma na rigakafin duniya yana cikin babban shakku. Don haka, bai kamata a yi tsammanin allurar rigakafin Covid za su ba da gudummawa don kawar da yaduwar kwayar cutar a cikin jama'a ko isa ga garkuwar garken garken. Wannan ya bayyana dalilan umarnin rigakafin da fasfo. |
| 56.) Bibiyar Watan Shida Bayan Kashi Na Hudu BNT162b2, Canetti & Regev-Yochay, 2022 | "Daga cikin mahalarta wadanda ba su kamu da kamuwa da cutar SARS-CoV-2 na baya ba, 6113 an haɗa su a cikin nazarin amsawar ban dariya da 11,176 a cikin nazarin tasirin rigakafin (Fig. S1 da Tables S2 da S3). Amsar antibody ya kai kusan makonni 4, ya ragu zuwa matakan da aka gani kafin kashi na huɗu ta hanyar 13 makonni, kuma an daidaita matakan sati na 6 bayan haka. na IgG da antibodies neutralizing sun kasance iri ɗaya bayan an karɓi allurai na uku da na huɗu kuma sun yi girma sama da matakan da aka gani bayan karɓar kashi na biyu (Hoto na 1A da 1B da Table S4).
An nuna madaidaicin abin da ya faru a cikin Hoto S2, kuma ana nuna tasirin rigakafin a ciki Hoto 1C. Karɓar kashi na huɗu na rigakafin BNT162b2 ya ba da ƙarin kariya daga kamuwa da cuta ta SARS-CoV-2 fiye da wanda aka bayar ta hanyar karɓar alluran rigakafin guda uku (tare da karɓar kashi na uku wanda ya faru aƙalla watanni 4 da suka gabata) (inganin rigakafin gabaɗaya, 41%; 95% tazarar amincewa [CI], 35 zuwa 47). Takaitaccen tasirin maganin rigakafin lokaci (wanda, a cikin bincikenmu, idan aka kwatanta adadin kamuwa da cuta tsakanin mahalarta waɗanda ba su riga sun kamu da cutar ba tun lokacin alurar riga kafi) sun ragu da lokaci, suna raguwa daga 52% (95% CI, 45 zuwa 58) a cikin makonni 5 na farko bayan rigakafin zuwa -2% (95% CI, -27 zuwa 17) a makonni 15.
 |
| 57) Ingancin mRNA-1273 akan SARS-CoV-2 omicron da bambance-bambancen delta, Tsang, 2022 | "Kashi na 2 na VE akan kamuwa da cutar omicron a cikin kwanaki 14-90 shine 44.0% (95% CI, 35.1-51.6%) amma ya ƙi da sauri. 3-dose VE shine 93.7% (92.2-94.9%) da 86.0% (78.1-91.1%) da 71.6% akan delta. da 69.7% (73.4-47.4%) akan kamuwa da cutar omicron a cikin kwanaki 40.5-53.5 da kuma> 14 days, bi da bi kamuwa da cuta na delta amma ƙananan tasiri akan kamuwa da cutar omicron, musamman a tsakanin mutanen da ba su da rigakafi, duk da haka, kashi 60-VE ya yi girma a asibiti tare da delta ko omicron. |
| 58) Adadin Sake kamuwa da cutar SARS-CoV-2 A lokacin Omicron Wave a Iceland, Eythorsson, 2022 | "11 536 PCR-tabbatacce mutane da aka hada. Ma'ana (SD) shekaru ne 34 (19) shekaru (tsakiyar, 31 shekaru; kewayon, 0-102 shekaru), 5888 (51%) maza ne, 2942 (25.5%) sun samu akalla 1 alluran rigakafi, da ma'ana (SD) lokaci daga farkon kamuwa da cuta kwanaki 287 (kwanaki 191) kamuwa da cuta. kewayo, 227-60 kwanaki); Yiwuwar sake kamuwa da cuta ya karu tare da lokaci daga kamuwa da cuta na farko (rabo maras kyau na watanni 642 da watanni 18, 3; 1.56% CI, 95-1.18) (Figure) kuma ya kasance mafi girma a cikin mutanen da suka karɓi 2 ko fiye da allurai idan aka kwatanta da kashi 1 ko ƙasa da maganin alurar riga kafi (rabo mara kyau, 1.42; 95% CI, 1.13-1.78)" |
| 59) Ingancin mRNA-1273 akan kamuwa da cuta da asibiti COVID-19 tare da sassan SARSCoV-2 Omicron: BA.1, BA.2, BA.2.12.1, BA.4, da BA.5, Tsang, 2022 | "Yayin da 3-dose VE a kan BA.1 kamuwa da cuta ya kasance mai girma kuma ya ragu a hankali, VE akan BA.2, BA.2.12.1, BA.4, da BA.5 kamuwa da cuta ya kasance farkon matsakaici zuwa babba (61.0% -90.6% 14-30 days post dose na uku) kuma ya ɓace da sauri. 4-dose VE, a kan kamuwa da cuta tsakanin BA.2 da BA.2.12.1. 4% -64.3%, kuma ya kasance ƙasa (75.7%) akan BA.30.8 5-14 kwanaki bayan kashi na huɗu, yana ɓacewa fiye da kwanaki 30 ga duk masu canji. |
| 60) Ingantacciyar rigakafin COVID-19 Sama da Watanni 13 Mai Rufe Lokacin Fitowar Bambancin Omicron a cikin Yawan Jama'ar Sweden, Yu, 2022 | "Magungunan alluran rigakafi guda biyu sun nuna kyakkyawan kariya mai dorewa daga kamuwa da cuta kafin Omicron (VE ya kasance sama da 85% na kowane lokaci), amma ƙarancin kariya daga kamuwa da cutar Omicron (ya ragu zuwa 43% ta mako huɗu kuma babu kariya ta mako 14). 80% ta mako 25) fiye da kamuwa da cuta." |
| 61) Dogon lokaci na COVID-19 yana haɓaka tasiri ta tarihin kamuwa da cuta da raunin asibiti da kuma buga rigakafi, Chemail, 2022 | Tasirin haɓakawa dangane da jerin farko shine 41.1% (95% CI: 40.0-42.1%) akan kamuwa da cuta da 80.5% (95% CI: 55.7-91.4%) akan COVID-19 mai tsanani, mai mahimmanci, ko mai kisa, sama da shekara guda bibi bayan mai haɓakawa. CI: 19-49.7%) a kan kamuwa da cuta da 95% (47.8% CI: 51.6-84.2%) a kan mai tsanani, m, ko m COVID-95. CI: 58.8-93.9%) ta wata na shida. raunin asibiti, ko nau'in rigakafin (BNT19b57.1 da mRNA-95)."
 
|
| 62) Abubuwan ban tsoro na gujewa kamuwa da cuta na haɓaka SARS-CoV-2 BQ da bambance-bambancen XBB, Wang, 2022 | “BQ.1, BQ.1.1, XBB, da XBB.1 sune bambance-bambancen SARS-CoV-2 da suka fi juriya har yau;
An rage raguwar ƙwayar ƙwayar ƙwayar ƙwayar cuta sosai, gami da mai haɓaka bivalent;
Duk magungunan rigakafin monoclonal na asibiti sun zama marasa aiki akan waɗannan bambance-bambancen;
Dangantakar ACE2 na waɗannan bambance-bambancen sun yi kama da nau'ikan iyayensu;
Bambancin BQ da XBB na SARS-CoV-2 Omicron yanzu suna haɓaka cikin sauri, maiyuwa ne saboda canjin kaddarorin kawar da ƙwayoyin cuta waɗanda ke samun ƙarin maye gurbinsu. Anan, mun bayar da rahoton cewa ba da jimawa ba na BQ.1, BQ.1.1, XBB, da XBB.1 ta hanyar sera daga alluran rigakafi da masu kamuwa da cutar ya yi rauni sosai, gami da sera daga daidaikun mutane da aka ƙarfafa tare da maganin WA1/BA.5 bivalent mRNA. Titers a kan BQ da XBB subvariants sun ragu da ninki 13-81 da 66-155, bi da bi, fiye da abin da aka gani zuwa yau. Magungunan rigakafi na monoclonal waɗanda ke da ikon kawar da ainihin bambance-bambancen Omicron ba su da aiki sosai a kan waɗannan sabbin sauye-sauyen, kuma an gano masu maye gurbi na mutum ɗaya. An samo waɗannan bambance-bambancen suna da alaƙa iri ɗaya na ACE2 kamar waɗanda suka gabace su. Tare, bincikenmu ya nuna cewa ɓangarorin BQ da XBB suna ba da babbar barazana ga allurar COVID-19 na yanzu, suna ba da duk wasu ƙwayoyin rigakafi masu izini, kuma wataƙila sun sami rinjaye a cikin yawan jama'a saboda fa'idarsu ta guje wa ƙwayoyin cuta. " |
| 63) Karancin neutralization na SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, da XBB.1 ta hanyar rigakafin mRNA na iyaye ko mai haɓaka BA.5-bivalent, Kurhade, 2022 | Sabbin sabbin hanyoyin SARS-CoV-2 Omicron, gami da BA.2-derived BA.2.75.2 da BA.5-derived BQ.1.1 da XBB.1, sun tara ƙarin maye gurbi wanda zai iya shafar tasirin rigakafin. bayan BA.23-bivalent-booster daga mutane tare da 94-4 na baya allurai na iyaye mRNA maganin rigakafi, ko 14-32 kwanaki bayan BA.5-bivalent-booster daga mutane da baya SARS-CoV-2 kamuwa da cuta da 4-15 allurai na iyaye mRNA rigakafi da sakamakon ya nuna cewa wani BA.32-bivalent-booster ya auna a high-5. Bayan haɓakawa; duk da haka, BA.2-bivalent-booster bai samar da tsayayyen tsaka-tsaki ba a kan sabuwar fitowar BA.2, BQ.4, ko XBB.5 wanda ya gabata kamuwa da cuta ya inganta girma da faɗin BA.4-bivalent-booster-elicited neutralization na gaba. |
| 64) Tasirin Cutar Coronavirus 2019 (COVID-19) Bivalent Vaccine, Shrestha, 2022 | “Binciken da aka yi na baya-bayan nan da aka gudanar a Cibiyar Kiwon Lafiyar Kiwon Lafiya ta Cleveland (CCHS) a Amurka.
Masu bincike sun haɗa da ma'aikata a daidai ranar da aka fara samun rigakafin COVID-19 na bivalent.
'Kariyar da aka bayar ta hanyar alurar riga kafi (wanda aka yi nazari a matsayin covariate mai dogara da lokaci) an kimanta shi ta hanyar amfani da Cox proportal hazards regression.'
Sakamakon binciken ya mayar da hankali kan ma'aikata 51,011 wanda 20,689 (41%) daga cikinsu sun rigaya sun kamu da cutar ta COVID-19, kuma ta yadda 42,064 (83%) suka sami aƙalla allurai biyu na rigakafin.
'Yawancin kamuwa da cuta a Ohio sun samo asali ne daga layin BA.4 ko BA.5 na bambancin Omicron a cikin makonni 10 na farko na binciken, dangane da bambance-bambancen sa ido na SARS-CoV-2 da ke samuwa daga Sashen Lafiya na Ohio. A watan Disamba, layin BQ.1, BQ.1.1, da BF.7 sun yi adadi mai yawa na cututtuka.'
"A ƙarshen binciken, 10804 (21%) an haɓaka rigakafin bivalent. Maganin bivalent shine maganin Pfizer a cikin 9595 (89%) da na Moderna a cikin sauran 1178. Gabaɗaya, ma'aikata 2452 (5%) sun sami COVID-19 a cikin makonni 13 na binciken.'
'Ƙididdigar tasirin maganin rigakafin gaba ɗaya daga samfurin shine 30% (95% CI, 20% - 39%)… lokacin da layin Omicron BA.4/BA.5 sune manyan nau'ikan yawo.'
"Bincike masu yawa iri-iri sun kuma gano cewa, kwanan nan na baya-bayan nan na COVID-19 na baya-bayan nan shi ne rage haɗarin COVID-19, kuma mafi yawan adadin alluran rigakafin da aka samu a baya ya fi haɗarin COVID-19." |
| 65) Ingancin mai haɓakawa na biyu idan aka kwatanta da mai haɓakawa na farko da kariya daga kamuwa da cutar SARS CoV-2 da ta gabata akan alamun Omicron BA.2 da BA.4/5 a Faransa, Tamandjou, 2023 | "Mun haɗa da alamun alamun ≥60 shekaru mutane da aka gwada don SARSCoV-2 a cikin Maris 21-Oktoba 30, 2022. Idan aka kwatanta da 181-210 kwanakin farko na farko, mai haɓakawa na biyu ya dawo da kariya tare da tasiri na 39% [95% CI: 38% - 41%] a cikin kwanaki 7-30 da aka samu kariya daga baya fiye da kwanaki XNUMX-XNUMX% na rigakafin. na farko mai ƙarfafawa, a daidai lokacin da ake yin allurar rigakafi." |
| 66) Extended SARS-CoV-2 RBD rigakafin haɓaka yana haifar da juriya da juriya na rigakafi na salula a cikin berayen., Gao, 2023 | i) Bincikenmu yana nuna haɗarin haɗari tare da ci gaba da amfani da masu haɓaka rigakafin rigakafi na SARS-CoV-2, yana ba da tasiri kai tsaye ga dabarun haɓaka rigakafin COVID-19 na duniya.
ii) Ko za a iya maimaita irin wannan sake kafa martanin rigakafin rigakafin da aka haifar ta hanyar ci gaba da aikace-aikacen masu haɓakawa, amma har yanzu ba a san su ba. Anan, mun kwatanta tasirin maimaita masu ƙarfafa rigakafin RBD tare da tsarin rigakafi na al'ada ga waɗanda ke da tsawaita dabarun rigakafin, a cikin ƙirar berayen Balb/c.
iii) Mun gano cewa illar kariya daga kariya ta walwala da rigakafi ta wayar salula da aka kafa ta hanyar rigakafin al'ada duk sun lalace sosai yayin tsawaita aikin rigakafin. Musamman, tsawaita allurar ba wai kawai ya lalata adadin da kuma kawar da ƙayyadaddun ƙwayoyin rigakafin ƙwayoyin cuta na RBD ba, har ma ya rage ƙwaƙwalwar jin daɗi na dogon lokaci.
iv) Wannan yana da alaƙa da juriya na rigakafi a cikin amsawar cibiyar germinal, tare da raguwar lambobi na ƙwayar ƙwayar ƙwayar cuta ta B da Tfh. Bugu da ƙari, mun nuna cewa ƙaddamar da rigakafi ya rage amsawar aiki na CD4 + da CD8 + T, ya hana yawan adadin ƙwaƙwalwar ajiyar ƙwayoyin T, da kuma daidaita maganganun PD-1 da LAG-3 a cikin ƙananan ƙwayoyin Te.
v) An kuma lura da karuwar kashi na ƙwayoyin Treg, tare da haɓakar haɓakar IL-10 mai mahimmanci. Tare, mun ba da shaida mai mahimmanci cewa maimaita gudanar da maganin rigakafi na RBD na iya yin mummunan tasiri ga martanin rigakafin da aka kafa ta hanyar rigakafin al'ada da haɓaka juriyar juriyar rigakafi.'
vi) Ci gaba da allurar rigakafi ya inganta samuwar sanannen juriyar juriya na rigakafi kuma yana da rauni sosai ga kafaffen amsawar rigakafi tare da tsarin al'ada, wanda aka tabbatar da raguwa mai yawa a cikin takamaiman antigen da amsa tantanin halitta T, asarar ƙwaƙwalwar rigakafi da nau'in micro-muhalli na rigakafi. |
| 67) Tasirin kamuwa da cuta ta farko, allurar rigakafi, da rigakafin matasan daga alamun BA.1 da BA.2 Omicron cututtuka da COVID-19 mai tsanani a Qatar, Altarawneh, Maris 2022 | "Masu bincike na Qatar sun binciki SARS-CoV-2 Omicron symptomatic BA.1 kamuwa da cuta, bayyanar cututtuka BA.2 kamuwa da cuta, BA.1 asibiti da mutuwa, da BA.2 asibiti da mutuwa, tsakanin Disamba 23, 2021 da Fabrairu 21, 2022. Masu binciken sun gudanar 6 na kasa, matching, gwajin-mara kyau case-control binciken da aka gudanar da NT-fizer162 binciken da aka gudanar don nazarin tasiri na NT2. maganin alurar riga kafi, mRNA-1273 (Moderna), rigakafi na halitta saboda kamuwa da cuta kafin kamuwa da cuta tare da bambance-bambancen pre-Omicron, da rigakafi na matasan daga kamuwa da cuta da riga-kafi. Tasirin allurar BNT2b46.1 na kashi biyu kawai ba shi da kyau a -95% (39.5% CI: -51.9-162), amma kusan duk mutane sun sami kashi na biyu watanni da yawa a baya. Amfanin allurar BNT2b1.1 guda uku kawai shine 95% (7.1% CI: 4.6-162%). Ingancin rigakafi na matasan na kamuwa da cuta ta farko da allurar BNT2b52.2 kashi biyu shine 95% (48.1% CI: 55.9-162%)." Mahimmin binciken shine "Babu bambance-bambancen da za a iya ganewa a cikin tasirin kamuwa da cuta na farko, alurar riga kafi, da rigakafi na matasan daga BA.2 da BA.55.1." |
| 68) Ingancin kashi na huɗu na rigakafin mRNA COVID-19 akan duk-dalilin mace-mace a cikin mazaunin wurin kulawa na dogon lokaci da kuma a cikin tsofaffi: A duk faɗin ƙasa, nazarin ƙungiyar jama'a a Sweden, Nordstrom, 2022 | "Daga kwanakin 7 bayan asali da kuma gaba, akwai mutuwar 1119 a cikin ƙungiyar LTCF a lokacin tsaka-tsakin tsaka-tsaki na kwanaki 77 da kuma iyakar kwanakin 126. A cikin kwanakin 7 zuwa 60, VE na kashi na hudu shine 39% (95% CI, 29-48), wanda ya ƙi zuwa 27-95% a cikin kwanaki 2-48 zuwa CI. 61. A cikin ƙungiyar dukan mutanen da ke da shekaru ≥126 shekaru, akwai mutuwar 80 a lokacin tsaka-tsakin tsaka-tsakin kwanaki 5753 da kuma iyakar kwanakin 73 a cikin kwanakin 143 zuwa 7, VE na kashi na hudu shine 60% (71% CI, 95-69), wanda ya ƙi zuwa 72% 54 (95%). 48 zuwa 60. |
| 69) Hadarin kamuwa da cuta, asibiti, da mutuwa har zuwa watanni 9 bayan kashi na biyu na rigakafin COVID-19: nazari na gaba, jimlar yawan jama'a a Sweden, Nordstrom, 2022 | "Don sakamakon SARS-CoV-2 kamuwa da cuta na kowane tsanani, tasirin rigakafin BNT162b2 ya ragu a hankali a kan lokaci, daga 92% (95% CI 92 zuwa 93; p <0 · 001) a cikin kwanaki 15-30, zuwa 47% (39 zuwa 55; p <0 · 001) zuwa 121% zuwa 180, kwana 23 zuwa 2. 41; p=0·07) daga ranar 211 zuwa gaba. Waning ya ɗan yi sannu a hankali don mRNA-1273, tare da tasirin rigakafin 96% (94 zuwa 97; p<0 · 001) a cikin kwanaki 15-30 da 59% (18 zuwa 79; p=0·012) daga ranar 181 zuwa gaba. Waning kuma ya ɗan ɗan yi sannu a hankali don heterologous ChAdOx1 nCoV-19 tare da maganin mRNA, wanda tasirin maganin ya kasance 89% (79 zuwa 94; p <0 · 001) a cikin kwanaki 15-30 da 66% (41 zuwa 80; p <0·001) daga ranar 121 gaba. Sabanin haka, tasirin maganin alurar riga kafi na homologous ChAdOx1 nCoV-19 shine 68% (52 zuwa 79; p<0 · 001) a cikin kwanaki 15-30, ba tare da wani tasiri da ake iya ganowa daga ranar 121 zuwa gaba (-19% [-98 zuwa 28]; p=0·49). Don sakamakon mummunan COVID-19, tasirin rigakafin ya ragu daga 89% (82 zuwa 93; p<0 · 001) a cikin kwanaki 15-30 zuwa 64% (44 zuwa 77; p <0·001) daga ranar 121 zuwa gaba. Gabaɗaya, akwai wasu shaidun da ke nuna ƙarancin tasirin allurar rigakafi a cikin maza fiye da na mata da kuma a cikin tsofaffi fiye da na matasa. ” |
| 70) Neutralization a kan BA.2.75.2, BQ.1.1, da XBB daga mRNA Bivalent Booster, Davis-Gardner, 2023 | "An yi amfani da FRNT a cikin layin salula na VeroE6/TMPRSS21 don kwatanta ayyukan tsaka-tsaki a cikin samfuran sinadarai da aka samu daga mahalarta cikin ƙungiyoyi uku: ƙungiyar farko ta ƙunshi mahalarta 12 7 zuwa 28 kwanaki bayan mai haɓaka monovalent guda ɗaya; na biyu, mahalarta 11 daga kwanaki 6 zuwa 57 bayan mai ƙarfafawa na biyu na monovalent; da na uku, 12 mahalarta 16 zuwa 42 kwanaki bayan bivalent booster.
A cikin dukkan ƙungiyoyin ƙungiyoyin uku, aikin kawar da kai ya yi ƙasa da duk ɓangarorin omicron fiye da na WA1/2020; aikin neutralizing ya kasance mafi ƙanƙanta a kan tsarin XBB (Figure 1 da siffa S2). A cikin ƙungiyar da ta karɓi mai haɓaka guda ɗaya, FRNT50 GMTs sun kasance 857 akan WA1/2020, 60 akan BA.1, 50 akan BA.5, 23 akan BA.2.75.2, 19 akan BQ.1.1, kuma ƙasa da iyakar ganowa akan XBB. A cikin ƙungiyar da ta karɓi masu haɓaka monovalent guda biyu, FRNT50 GMTs sun kasance 2352 akan WA1/2020, 408 akan BA.1, 250 akan BA.5, 98 akan BA.2.75.2, 73 akan BQ.1.1, da 37 akan XBB. Sakamako a cikin waɗannan ƙungiyoyin guda biyu sun yi daidai da titers neutralization a kan BA.1 da BA.5 waɗanda suka yi ƙasa da sau 5 zuwa 9 fiye da na WA1/2020 da kuma na tsaka tsaki a kan BA.2.75.2, BQ.1.1, da XBB waɗanda suka yi ƙasa da sau 23 zuwa 63 a kan WA1/2020." |
| 71) Tsare Tsallakewa ta hanyar SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, da BA.5, Hachmann, 2022 | "Wata shida bayan farkon alluran BNT162b2 guda biyu, matsakaicin tsaka-tsakin antibody pseudovirus titer ya kasance 124 akan WA1/2020 amma kasa da 20 akan duk samfuran omicron da aka gwada. subvariant, 5783 da BA.1 subvariant, 2020 a kan BA.900 subvariant, da 1 a kan BA.829 ko BA.2 subvariant.
Daga cikin mahalarta da ke da tarihin Covid-19, matsakaicin tsaka-tsakin antibody titer ya kasance 11,050 akan warewar WA1/2020, 1740 akan BA.1 subvariant, 1910 akan BA.2 subvariant, 1150 akan BA.2.12.1 subvariant, da 590 a kan BA.4. |
